Skip to main content
Premium Trial:

Request an Annual Quote

Roche's HIV and HCV MDx Get CE Mark

NEW YORK (GenomeWeb) – Roche today said that its Cobas HIV-1 and HCV next-generation viral load monitoring assays have received CE marking.

The Cobas HIV-1 assay simultaneously amplifies and detects two separate regions of the HIV-1 genome to quantify the amount of viral RNA in the patient's blood. The Cobas HCV assay employs the firm's dual-probe approach to detect hepatitis C RNA. Both assays are available for use on the Cobas 6800 and 8800 systems.

The two molecular diagnostic systems are fully automated platforms for blood donor screening, viral load monitoring, women's health, and microbiology testing. Roche said in a statement that the viral load portfolio on the 6800 and 8800 systems "will provide laboratories with improved productivity and the ability to deliver results for rapid clinical decisions."

Roche first unveiled the Cobas platforms in May, 2013 and received the CE mark for them in September, 2014.

Roche also announced today that the Cobas HIV-1 and HCV assays are commercially available in geographies that recognize CE marking. The assays are not currently available in theUS.

In a statement, the firm said it will launch Cobas cytomegalovirus and Cobas hepatitis B assays in the coming months. 

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.